oral sel. IDO1 dioxygenase inhibitor

100 mg QD, in I/O combo studies for cancer

acts on apo-IDO1 displacing heme co-factor

Mol. Cancer Ther., Dec. 9, 2020

BMS, Princeton, NJ / Flexus, San Carlos, CA

Chemical structure of molecule linrodostat inhibitor

Bristol Myers Squibb (BMS) oral selective heme-displacing IDO1 inhibitor


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: